Boardroom Alpha
Boardroom Alpha
AVAH · Current Report (Form 8-K) · Filed August 24, 2026

Aveanna Healthcare Holdings Inc — Current Report (Form 8-K)

Form
8-K
Filed
August 24, 2026
Period
Aug 24, 2026
Ticker
AVAH
Accession
0001193125-26-363654
Boardroom Alpha · Filing insights

Selling stockholders completed a secondary offering of 15,000,000 Aveanna shares at $11.75; company did not issue shares or receive proceeds.

About Aveanna Healthcare Holdings Inc
Market cap
$3.0B
1Y TSR
+76.7%
3Y TSR
+90.7%
Board grade
B
Sector
Healthcare
CEO
Jeff Shaner
Last annual meeting: May 29, 2026 · View full Aveanna Healthcare Holdings Inc profile →
8-K
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 24, 2026

 

 

 

LOGO

Aveanna Healthcare Holdings Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-40362   81-4717209

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

400 Interstate North Parkway SE  
Atlanta, Georgia   30339
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code: 770 441-1580

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, par value $0.01 per share   AVAH   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 


Item 8.01 Other Events.

On August 20, 2026, Aveanna Healthcare Holdings Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) by and among the Company, certain selling stockholders (the “Selling Stockholders”), including affiliates of J.H. Whitney Equity Partners VII, LLC and certain current and former directors and officers of the Company, and RBC Capital Markets, LLC (the “Underwriter”) with respect to the offer and sale by the Selling Stockholders (the “Secondary Offering”) of 15,000,000 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”) at a public offering price of $11.75 per share. In addition, the Selling Stockholders granted the Underwriter a 30-day option to purchase up to an additional 2,250,000 shares of the Company’s Common Stock. The Secondary Offering closed on August 24, 2026. The Company did not issue or sell any Common Stock in the Secondary Offering and did not receive any proceeds from the Secondary Offering.

The foregoing description of the Underwriting Agreement is qualified in its entirety by the terms of such agreement, which is incorporated herein by reference and attached to this report as Exhibit 1.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit
Number

    
1.1    Underwriting Agreement, dated August 20, 2026, by and among Aveanna Healthcare Holdings Inc., the selling stockholders named therein, and RBC Capital Markets, LLC
5.1    Opinion of King & Spalding LLP
23.1    Consent of King & Spalding LLP (included in Exhibit 5.1 above)
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      AVEANNA HEALTHCARE HOLDINGS INC.
Date: August 24, 2026     By:  

/s/ Matthew Buckhalter

     

Matthew Buckhalter

Chief Financial Officer

(Principal Financial Officer)

From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Aveanna Healthcare Holdings Inc (AVAH)

Reference

Frequently asked questions

When did Aveanna Healthcare Holdings Inc file this 8-K?
Aveanna Healthcare Holdings Inc (AVAH) filed this Current Report (Form 8-K) with the SEC on August 24, 2026. The accession number assigned by EDGAR is 0001193125-26-363654.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Selling stockholders completed a secondary offering of 15,000,000 Aveanna shares at $11.75; company did not issue shares or receive proceeds. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Aveanna Healthcare Holdings Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Aveanna Healthcare Holdings Inc has filed under CIK 1832332, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer